These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe. Hort J; Bartos A; Pirttilä T; Scheltens P Eur J Neurol; 2010 Jan; 17(1):90-6. PubMed ID: 19659752 [TBL] [Abstract][Full Text] [Related]
27. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population. Johansson P; Mattsson N; Hansson O; Wallin A; Johansson JO; Andreasson U; Zetterberg H; Blennow K; Svensson J J Alzheimers Dis; 2011; 24(3):537-46. PubMed ID: 21297262 [TBL] [Abstract][Full Text] [Related]
31. [The role of CSF markers in the early diagnosis of Alzheimer's disease]. Vos SJ; Visser PJ; Verhey FR Tijdschr Psychiatr; 2011; 53(9):647-53. PubMed ID: 21898322 [TBL] [Abstract][Full Text] [Related]
32. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample. Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339 [TBL] [Abstract][Full Text] [Related]
33. Impact of the 2008-2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study. Gabelle A; Dumurgier J; Vercruysse O; Paquet C; Bombois S; Laplanche JL; Peoc'h K; Schraen S; Buée L; Pasquier F; Hugon J; Touchon J; Lehmann S J Alzheimers Dis; 2013; 34(1):297-305. PubMed ID: 23186986 [TBL] [Abstract][Full Text] [Related]
34. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies. Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322 [TBL] [Abstract][Full Text] [Related]
35. CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Wallin AK; Blennow K; Andreasen N; Minthon L Dement Geriatr Cogn Disord; 2006; 21(3):131-8. PubMed ID: 16391474 [TBL] [Abstract][Full Text] [Related]
36. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls. Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147 [TBL] [Abstract][Full Text] [Related]
37. The neurofilament heavy chain (NfH) in the cerebrospinal fluid diagnosis of Alzheimer's disease. Brettschneider J; Petzold A; Schottle D; Claus A; Riepe M; Tumani H Dement Geriatr Cogn Disord; 2006; 21(5-6):291-5. PubMed ID: 16484807 [TBL] [Abstract][Full Text] [Related]
38. Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease. Formichi P; Battisti C; Radi E; Federico A J Cell Physiol; 2006 Jul; 208(1):39-46. PubMed ID: 16447254 [TBL] [Abstract][Full Text] [Related]
39. Neurochemical dementia diagnostics: assays in CSF and blood. Lewczuk P; Hornegger J; Zimmermann R; Otto M; Wiltfang J; Kornhuber J Eur Arch Psychiatry Clin Neurosci; 2008 Nov; 258 Suppl 5():44-9. PubMed ID: 18985294 [TBL] [Abstract][Full Text] [Related]
40. [New biomarkers for Alzheimer's disease in cerebrospinal fluid and blood]. Vogelgsang J; Wiltfang J Nervenarzt; 2019 Sep; 90(9):907-913. PubMed ID: 31407045 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]